Advanced Breast Cancer
Conditions
Brief summary
To study the epidemiological trends and characteristics for advanced breast cancer patients, to analyze these trends and report the results
Detailed description
In this study, the investigators conducted a hospital-based retrospective clinical study, recruiting female advanced breast cancer patients from 14 tertiary hospitals at 7 classic geographic regions, to study the clinical epidemiologic characteristics of advanced breast cancer and the current standard of clinical diagnosis and treatment in order to provide references for standardized treatment therapy, and to improve the quality of life and prolong survival time. To study the epidemiological trends and characteristics for advanced BC patients, to analyze these trends and report the results. To learn about the current treatment therapy for advanced BC patients in different areas in China.To provide references for standardized treatment therapy, to improve the quality of patients' life and to prolong the survival time for the advanced BC patients.To assess the different treatment therapies for advanced BC with consideration of economic cost-effectiveness
Interventions
DRUGstandard therapy
standard therapy for advanced/metastatic breast cancer
Sponsors
Chinese Academy of Medical Sciences
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* diagnosed as advanced breast cancer during Jan1st,2012-Dec31st,2014 * complete with surgical pathology data, auxiliary treatment, there is a clear recurrence, transfer time, place, transfer of recurrence after treatment, and curative effect evaluation details.In any age, ethnic group cases.
Exclusion criteria
* no available medical record
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Survival status at 3 years | 3 years | percentage of patients still alive at 3 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 3 years | Progression-free survival of first line therapy |
| Survival status at 5 years | 3 years | percentage of patients still alive at 5 years |
Countries
China
Contacts
Primary ContactBinghe Xu
Outcome results
None listed